Skip to main content
Premium Trial:

Request an Annual Quote

Roche to Distribute Aclara s Arteas LabCards

NEW YORK, Nov. 7 – Aclara BioSciences said Wednesday that Roche Applied Science had agreed to market its Arteas LabCard product, which is designed to allow researchers to run assays using small amounts of consumables. 

Roche Applied Science, a business unit of Roche Diagnostics, will begin launching the Arteas product in the first quarter of next year. Until then, Aclara will continue selling its LabCards. 

Roche has also obtained rights to negotiate to market additional Aclara products.

"After a thorough evaluation, we concluded that ACLARA possessed an unusual combination of strengths in both microfluidics and application chemistries, which together solve important customer needs,” Juergen Flach, general manager of Roche Diagnostics Corporation, said in a statement. 

Aclara said that LabCard require 10 – 100 times less consumables than conventional microwell plates.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.